# Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease

> **NCT00841373** · PHASE1,PHASE2 · COMPLETED · sponsor: **Southern New England Retina Associates** · enrollment: 1 (actual)

## Conditions studied

- Retinal Ischemia

## Interventions

- **PROCEDURE:** Panretinal Photocoagulation
- **PROCEDURE:** Panretinal Photocoagulation and intravitreal injection of ranibizumab

## Key facts

- **NCT ID:** NCT00841373
- **Lead sponsor:** Southern New England Retina Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-01
- **Final completion:** 2010-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2014-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00841373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00841373, "Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00841373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*